ESC 365 - Target populations and treatment cost for bempedoic acid and PCSK9 inhibitors: a simulation study in a contemporary CAD cohort

ESC Premium Access

Target populations and treatment cost for bempedoic acid and PCSK9 inhibitors: a simulation study in a contemporary CAD cohort

Session: Highlights from the Young on cutting edge therapy for lowering lipids

Topic: Lipid-Lowering Agents

Speaker: Doctor C. Blaum (Hamburg, DE)

Event: ESC Congress 2021 - The Digital Experience

Congress Presentation

Add to my library

About the speaker

Doctor Christopher Blaum

University Heart and Vascular Centre Hamburg (UHZ), Hamburg (Germany)

1 presentation

0 follower

4 more presentations in this session

Impact of ACLY on type 2 diabetes in UK Biobank: A Mendelian randomisation study

Speaker: Doctor A. Stiby (Oxford, GB)

Lipid testing trends before and after hospitalization for myocardial infarction among adults in the U.S., 2008-2019

Speaker: Ms C. Wiener (Durham, US)

The prevalence of statin intolerance worldwide: a systematic review and meta-analysis with 4,143,517 patients

Speaker: Doctor I. Bytyci (Pristina, XK)

Acute arterial events across all vascular territories in the FOURIER trial

Speaker: Doctor K. Oyama (Sendai, JP)

Access the full session

Highlights from the Young on cutting edge therapy for lowering lipids

Speakers: Doctor C. Blaum, Doctor A. Stiby, Ms C. Wiener, Doctor I. Bytyci, Doctor K. Oyama

About the event

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources